Kingswood Wealth Advisors LLC Makes New $241,000 Investment in Hims & Hers Health, Inc. $HIMS

Key Points

• Kingswood Wealth Advisors LLC made a new investment of $241,000 in Hims & Hers Health, acquiring 4,837 shares in the second quarter.
• Research firms have downgraded Hims & Hers Health stock, with Zacks Research moving it from a "strong-buy" to a "hold" rating, and Truist Financial lowering its price target from $48.00 to $37.00.
• Insider transactions indicate CEO Andrew Dudum sold 660,000 shares for approximately $33.4 million, representing a 22.96% decrease in his ownership of the stock.

Kingswood Wealth Advisors LLC acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 4,837 shares of the company's stock, valued at approximately $241,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after buying an additional 227 shares during the period. True Vision MN LLC lifted its holdings in Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after buying an additional 328 shares during the period. Allworth Financial LP lifted its holdings in Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after buying an additional 334 shares during the period. Signaturefd LLC lifted its holdings in Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after buying an additional 388 shares during the period. Finally, Kilter Group LLC lifted its holdings in Hims & Hers Health by 1.0% in the 1st quarter. Kilter Group LLC now owns 43,989 shares of the company's stock worth $1,300,000 after buying an additional 450 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HIMS. Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Finally, Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Down 7.3%

Hims & Hers Health stock opened at $53.98 on Friday. The firm has a market cap of $12.20 billion, a price-to-earnings ratio of 67.48, a PEG ratio of 3.64 and a beta of 2.25. The stock has a fifty day simple moving average of $50.86 and a two-hundred day simple moving average of $48.00. Hims & Hers Health, Inc. has a 12 month low of $17.36 and a 12 month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business's quarterly revenue was up 72.6% on a year-over-year basis. During the same quarter last year, the business earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 660,000 shares of the firm's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. This trade represents a 22.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 145,000 shares of the firm's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer owned 128,984 shares in the company, valued at approximately $7,139,264.40. This trade represents a 52.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,622,741 shares of company stock worth $83,695,469 in the last ninety days. Insiders own 13.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.